Propafenone Dosing in Renal Dysfunction

Guideline Recommendations

• The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend that renal dysfunction is not a reason for dose adjustment of propafenone, as stated in the 2015 ACC/AHA/HRS guidelines 1
• The European Society of Cardiology guidelines suggest using caution in the presence of conduction system disease and renal impairment for propafenone SR, but this refers to monitoring rather than mandatory dose reduction 2

Contraindications and Precautions

• The American College of Cardiology recommends avoiding propafenone entirely in patients with structural heart disease or ischemic heart disease, reduced left ventricular ejection fraction or heart failure, sinus or AV conduction disease without a pacemaker, and Brugada syndrome 1
• The European Society of Cardiology recommends avoiding propafenone in patients with reduced left ventricular ejection fraction or heart failure 2

Standard Dosing

• The American College of Cardiology and European Society of Cardiology recommend standard dosing of propafenone, with immediate-release formulation at 150-300 mg three times daily (maximum 900 mg/day) and extended-release formulation at 225-425 mg twice daily (maximum 850 mg/day), regardless of renal function 1, 2

Monitoring Recommendations

• The European Society of Cardiology recommends ECG monitoring for QRS widening (>25% increase above baseline warrants dose reduction or discontinuation) in all patients, regardless of renal function 2
• The American College of Cardiology and European Society of Cardiology recommend assessing for structural heart disease and hepatic function before initiating therapy, as these are the critical safety concerns, not renal function 1, 2